Transthyretin Amyloidosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Transthyretin Amyloidosis Treatment Market Report is Segmented by Type (ATTR-CM (Transthyretin Amyloid Cardiomyopathy) and ATTR-PN (Transthyretin Amyloid Polyneuropathy)), Therapy (Targeted Therapy and Supportive Therapy), Disease Type (Hereditary Amyloidosis, Wild-Type Amyloidosis, and Other Disease Type), Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, and Other Distribution Channel), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The Report Offers Market Size and Forecast in Terms of Value (USD) for the Above Segments.

Transthyretin Amyloidosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Transthyretin Amyloidosis Treatment Industry Overview

The transthyretin amyloidosis treatment market is moderately consolidated in nature due to the presence of limited companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known, including Pfizer Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals Inc., Intellia Therapeutics Inc., and BridgeBio Inc.

Transthyretin Amyloidosis Treatment Market Leaders

  1. Pfizer Inc.

  2. Ionis Pharmaceuticals

  3. Alnylam Pharmaceuticals, Inc.

  4. BridgeBio Inc

  5. Intellia Therapeutics, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Transthyretin Amyloidosis Treatment Market Concentration

Transthyretin Amyloidosis Treatment Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?